Martin ZapataLaguado· @zapatalaguadomd · X·· 2 天前评分70
正文 · 原文
#ESMO26 | CAPItello-281 update: Capivasertib + abiraterone improves OS in PTEN-deficient mHSPC (HR 0.82; 57.4 vs 46.5 months), with sustained rPFS benefit.
A promising first-line strategy! @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily#ProstateCancer
71 浏览 · 0 赞 · 1 转发 · 0 回复
会议摘要
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281
https://esmocongress.esmo.org来源：Martin ZapataLaguado · x.com